Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual PropertyPosted by On




CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount. Enveric plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-



Source link

Business

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.